Impact of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors in

Status Recruiting

Clinical Trial Summary

The study of the blood concentration of ITK what are pazopanib and cabozantinib at 1 month and 3 months from the start of treatment will allow to evaluate the impact of renal failure on their efficacy and toxicity in patients with metastatic kidney cancer.

Clinical Trial Description

This study involves patients treated with cabozantinib or pazopanib in their metastatic renal cancer. Indeed, the aim of this study is to assess the blood concentration of these two drugs as well as their tolerance, in relation to their renal function (normal renal function or moderate or severe renal failure). Pazopanib and cabozantinib are kinase inhibitors that are indicated for a number of cancer conditions, including metastatic kidney cancer. Both of these oral therapies require a daily intake of the drug to ensure its effectiveness. For this, the patient must have optimal compliance and benefit from regular follow up to assess clinical and biological tolerance. Chronic renal failure is a factor that may impact the efficacy and toxicity of pazopanib and cabozantinib. This may be due either to a elimination default of the drug or to much elimination if the drug is filtered after dialysis. As a result, kinase inhibitors could be impacted by chronic renal failure and thus modify the safety and efficacy of the treatment. A study-specific blood test will be taken at 1 month and at 3 months during a consultation (this blood test is in addition to the routine blood test). Its analysis will evaluate the quantity of medication present in the blood. The other objective of this study is to evaluate the side effects of the drug taken by the patient (pazopanib or cabozantinib). This will alow to propose possible dose adjustments for each of these treatments and thus improve the management of these patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04823923
Study type	Interventional
Source	Institut du Cancer de Montpellier - Val d'Aurelle
Contact	Aurore MOUSSION
Phone	04 67 61 31 02
Email	DRCI-icm105@icm.unicancer.fr
Status	Recruiting
Phase	N/A
Start date	December 6, 2021
Completion date	March 2026

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01961583` - [18F]Fluciclatide PET Imaging of Pazopanib Response	Phase 2
Completed	`NCT00001302` - A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833	Phase 1
Completed	`NCT01896778` - Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer	N/A
Enrolling by invitation	`NCT02287987` - CLamp vs Off Clamp Kidney During Partial Nephrectomy	N/A
Recruiting	`NCT04644432` - Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma	Phase 2
Active, not recruiting	`NCT05817604` - Stereotactic Body Radiotherapy (SBRT) for Medically Inoperable Localised Renal Tumors (SABINA Trial)
Completed	`NCT00888641` - A Pilot Study of Renal Hypothermia During Partial Nephrectomy	Phase 1
Completed	`NCT00199875` - Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250	Phase 1
Recruiting	`NCT00994188` - A Clinical Study of the Living Renal Transplantation With Restored Kidneys Between Family Members	N/A
Recruiting	`NCT02346435` - The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry
Completed	`NCT01087060` - Detection of Renal Malignancy of Complicated Renal Cysts	N/A
Recruiting	`NCT04258462` - Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors	Phase 2
Recruiting	`NCT00898365` - Study of Kidney Tumors in Younger Patients
Recruiting	`NCT03996850` - SPECT/CT for the Characterization of Renal Masses
Not yet recruiting	`NCT04681690` - German National Registry for NSS
Not yet recruiting	`NCT05135832` - Patient Reported Outcomes by Patients With Metastatic Renal Cell Carcinoma	N/A
Recruiting	`NCT04602702` - Hyper-Personalized Medicine Using Patient Derived Xenografts (PDXovo) for Metastatic Solid Tumors
Terminated	`NCT00005655` - Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer	Phase 1
Recruiting	`NCT05887245` - Clinical Significance of Adherent Perinephric Fat in Patients Undergoing Partial Nephrectomy
Recruiting	`NCT06467097` - Systemic Treatment Alone Versus Systemic Treatment Plus Radiotherapy in Oligometastatic Renal Cell Carcinoma	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Impact of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors in Patients Treated for Metastatic Kidney Cancer — IREKI

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms